Hillsdale Investment Management Inc. Takes $4.30 Million Position in Rhythm Pharmaceuticals, Inc. $RYTM

Hillsdale Investment Management Inc. purchased a new position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 42,600 shares of the company’s stock, valued at approximately $4,302,000. Hillsdale Investment Management Inc. owned about 0.06% of Rhythm Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Rhythm Pharmaceuticals by 4.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,568 shares of the company’s stock worth $259,000 after buying an additional 110 shares in the last quarter. Captrust Financial Advisors grew its position in Rhythm Pharmaceuticals by 0.7% in the second quarter. Captrust Financial Advisors now owns 17,471 shares of the company’s stock worth $1,104,000 after acquiring an additional 114 shares in the last quarter. Smartleaf Asset Management LLC grew its position in Rhythm Pharmaceuticals by 97.2% in the third quarter. Smartleaf Asset Management LLC now owns 286 shares of the company’s stock worth $29,000 after acquiring an additional 141 shares in the last quarter. Teacher Retirement System of Texas increased its stake in Rhythm Pharmaceuticals by 1.5% during the third quarter. Teacher Retirement System of Texas now owns 12,960 shares of the company’s stock worth $1,309,000 after acquiring an additional 188 shares during the last quarter. Finally, California State Teachers Retirement System raised its position in Rhythm Pharmaceuticals by 0.5% during the second quarter. California State Teachers Retirement System now owns 42,917 shares of the company’s stock valued at $2,712,000 after purchasing an additional 196 shares during the period.

Insider Transactions at Rhythm Pharmaceuticals

In other Rhythm Pharmaceuticals news, CFO Hunter C. Smith sold 4,385 shares of the business’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $101.26, for a total value of $444,025.10. Following the completion of the sale, the chief financial officer directly owned 110,512 shares of the company’s stock, valued at $11,190,445.12. The trade was a 3.82% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Pamela J. Cramer sold 3,350 shares of the company’s stock in a transaction dated Thursday, December 11th. The stock was sold at an average price of $111.00, for a total transaction of $371,850.00. Following the completion of the transaction, the insider owned 20,814 shares in the company, valued at $2,310,354. This represents a 13.86% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 25,003 shares of company stock valued at $2,589,015 in the last quarter. 6.10% of the stock is currently owned by company insiders.

Rhythm Pharmaceuticals Trading Down 3.3%

NASDAQ:RYTM opened at $99.78 on Monday. The company has a market cap of $6.66 billion, a price-to-earnings ratio of -32.19 and a beta of 2.00. Rhythm Pharmaceuticals, Inc. has a twelve month low of $45.90 and a twelve month high of $122.20. The stock has a fifty day simple moving average of $105.41 and a 200-day simple moving average of $103.50.

Rhythm Pharmaceuticals News Roundup

Here are the key news stories impacting Rhythm Pharmaceuticals this week:

• Positive Sentiment: RBC/ Royal Bank initiated coverage and/or upgraded RYTM with an outperform/moderate-buy stance, bringing renewed institutional attention and a formal buy-style endorsement that can support near-term demand. RBC initiates coverage
• Positive Sentiment: Several sell-side firms have raised price targets and reiterated buy/overweight ratings (Wells Fargo, Morgan Stanley, Citizens/JMP, UBS, TD Cowen), reinforcing a bullish consensus and higher upside expectations. MarketBeat analyst roundup
• Positive Sentiment: Operational narrative improving: a Yahoo Finance piece highlights Imcivree revenue ramp and updated management targets — if execution continues, this supports medium-term revenue growth that underpins analyst optimism. Imcivree revenue and targets
• Neutral Sentiment: Zacks moved coverage from “strong sell” to “hold” and flagged RYTM as positioned to potentially beat upcoming earnings — these are watchpoints that reduce perceived downside but are not immediate catalysts without reported results. Zacks coverage and earnings outlook
• Negative Sentiment: Insider selling by CFO Hunter C. Smith: filings show sales of several thousand shares (transactions reported for Feb. 17 and Feb. 19 at ~ $101 per share). While the amounts are a small percentage of his total holding, such sales can trigger near-term selling pressure or investor concern about insider conviction. CFO sale disclosure

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the company. HC Wainwright lifted their target price on Rhythm Pharmaceuticals from $123.00 to $125.00 and gave the stock a “buy” rating in a report on Tuesday, January 20th. Morgan Stanley reaffirmed an “overweight” rating and set a $150.00 price objective on shares of Rhythm Pharmaceuticals in a research note on Thursday, December 11th. The Goldman Sachs Group boosted their price objective on shares of Rhythm Pharmaceuticals from $141.00 to $157.00 and gave the company a “buy” rating in a research report on Friday, December 12th. Zacks Research raised shares of Rhythm Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 17th. Finally, Canaccord Genuity Group upped their price target on shares of Rhythm Pharmaceuticals from $114.00 to $141.00 and gave the company a “buy” rating in a report on Friday, December 12th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Rhythm Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $131.50.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.